Study summary

HER2-targeted antibody plus chemotherapy shrank 60% of HER2-positive salivary cancers

Trastuzumab and docetaxel trial · 16 people treated, phase 2 · Published October 2025, Japanese Journal of Clinical Oncology

60.0%response rate

What was tested

Trastuzumab with docetaxel chemotherapy for recurrent or metastatic HER2-positive salivary gland cancer.

What they found

What it means

Led to approval of trastuzumab for HER2-positive salivary cancer in Japan.

Jpn J Clin Oncol, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.